Formycon AG Logo

Formycon AG

ISIN: DE000A1EWVY8 | Ticker: FYB | LEI: 39120005TZ76GQOY8Z19
Sector: Health CareSub-Industry: Biotechnology
Country: Germany

About Formycon AG

Company Description

Formycon is a world-leading, independent developer of high-quality biosimilars, meaning follow-on products to biopharmaceutical medicines already on the market.

Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company’s activities span the entire range from technical- pharmaceutical development to clinical trials all the way through to preparation and submission of dossiers for regulatory approval.

We develop biosimilar medicines to meet the high standards of the world’s most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia. We will continue to expand our position as a globally operating company in the growth market of biosimilars in line with our growth strategy.

Year founded

1999

Served area

Worldwide

Headcount

171

Headquarters

Fraunhoferstraße 15, 82152 Martinsried/Planegg – Germany

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2022

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

DE000A1EWVY8

LEI

39120005TZ76GQOY8Z19

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Frankfurt Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.